Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method - 10/08/11
, Linda S. Hynan, PhD b, c, Rafia Bhore, PhD b, Fransell Copeland Riley, MS b, Ian L. Guevara, MD a, Pearl Grimes, MD d, James J. Nordlund, MD e, Marta Rendon, MD f, Susan Taylor, MD g, Ronald W. Gottschalk, MD, FRCPC h, Nnenna G. Agim, MD a, Jean-Paul Ortonne, MD i
Correspondence to: Amit G. Pandya, MD, Department of Dermatology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9190.Abstract |
Background |
The Melasma Area and Severity Index (MASI), the most commonly used outcome measure for melasma, has not been validated.
Objective |
We sought to determine the reliability and validity of the MASI.
Methods |
After standardized training, 6 raters independently rated 21 patients with mild to severe melasma once daily over a period of 2 days to determine intrarater and interrater reliability. Validation was performed by comparing the MASI with the melasma severity scale. The darkness component of the MASI was validated by comparing it with the difference between mexameter scores for affected versus adjacent normal-appearing skin. The area component of the MASI was validated by comparing it with the area of each section of the face determined by computer-based measurement software.
Results |
The MASI score showed good reliability within and between raters and was found to be valid when compared with the melasma severity scale, mexameter scores, and area measurements. Homogeneity assessment by raters showed the least agreement and can be removed from the MASI score without any loss of reliability.
Limitations |
Patients were limited to Hispanic, African, and Asian backgrounds.
Conclusion |
The MASI is a reliable measure of melasma severity. Area of involvement and darkness are sufficient for accurate measurement of the severity of melasma and homogeneity can be eliminated.
Le texte complet de cet article est disponible en PDF.Key words : clinical trials, evidence-based medicine, melasma, outcome measure, pigmentation, validation
Abbreviations used : ANOVA, MASI, MSS
Plan
| Supported by an unrestricted educational grant from Galderma International. |
|
| Disclosure: Drs Pandya, Grimes, Nordlund, Ortonne, Rendon and Taylor are members of the Pigmentary Disorders Academy and receive honoraria as consultants from Galderma International for their work on behalf of the Academy. Drs Hynan, Bhore, Guevara, Gottschalk, and Agim, and Ms Copeland Riley have no conflicts of interest to declare. |
|
| Reprints not available from the authors. |
Vol 64 - N° 1
P. 78 - janvier 2011 Retour au numéro
Article précédent
- Announcing a New Online Feature
- Cigarette smoking and malignant melanoma: A case-control study
- Maria C. Kessides, Lee Wheless, Judith Hoffman-Bolton, Sandra Clipp, Rhoda M. Alani, Anthony J. Alberg
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?